UNSPSC 51391609: Hydroxyamphetamine

This classification denotes an adrenergic agent with the molecular formula C9H13NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FQR280JW2N, chemically known as phenol, 4-(2-aminopropyl)- but generally known as hydroxyamfetamine, which bears US NIH Compound Identifier 644000. European Medicines Agency schedules Hydroxyamfetamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08075MIG. The term HYDROXYAMFETAMINE is an International Non-Proprietary Name.

HYDROXYAMFETAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, HYDROXYAMPHETAMINE remains the US FDA Preferred Term for this commodity. Hydroxyamphetamine bears US NLM identifiers UMLS ID C0030140 and NCI Concept Code C61787. SMILES: OC1CCC(CC(N)C)CC1.

UNSPSC 51391609 Hydroxyamphetamine is a Commodity code that in recent state and local procurement activity encompasses the purchase of naloxone and related drug-response supplies for community health and emergency preparedness. The code sees demand from county health departments and state health agencies procuring pharmaceutical products and drug-deactivation systems to support overdose-response and public-health initiatives. Solicitations under this code typically specify annual unit quantities, delivery schedules to designated health facilities, and compliance requirements including drug-free workplace certification, E-Verify authorization, and insurance coverage mandates. Contracting vehicles range from competitive sealed-bid processes with fixed-fee pricing to exploratory requests for information designed to assess vendor capacity before formal procurement.

Recent activity is concentrated in Florida and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug-deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a bid deadline of July 26, 2023 and a two-year initial contract term with one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs, with response due April 3, 2026, as a preliminary market-intelligence phase intended to inform subsequent formal procurement. The RFI stage suggests the state is still evaluating contracting models and vendor qualifications before committing to specific contract values or timelines.